For the year ending 2025-12-31, XENE made $7,500K in revenue. -$345,910K in net income. Net profit margin of -4612.13%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Collaboration revenue (note 10) | 7,500 | - | ||
| Research and development | 300,938 | 210,394 | ||
| General and administrative | 79,632 | 68,904 | ||
| Total operating expenses | 380,570 | 279,298 | ||
| Loss from operations | -373,070 | -279,298 | ||
| Interest income | 26,828 | 41,943 | ||
| Unrealized fair value gain on trading securities | 0 | - | ||
| Foreign exchange gain (loss) | 1,348 | -1,064 | ||
| Total other income | 28,176 | 40,879 | ||
| Loss before income taxes | -344,894 | -238,419 | ||
| Income tax recovery (expense) (note 14) | 1,016 | -4,089 | ||
| Net loss | -345,910 | -234,330 | ||
| Net loss attributable to common shareholders | - | -234,330 | ||
| Basic EPS | -4.36 | -3.01 | ||
| Diluted EPS | -4.36 | -3.01 | ||
| Basic Average Shares | 79,253,751 | 77,894,643 | ||
| Diluted Average Shares | 79,253,751 | 77,894,643 | ||
Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Inc. (XENE)